Target Name: CCT3
NCBI ID: G7203
Review Report on CCT3 Target / Biomarker Content of Review Report on CCT3 Target / Biomarker
CCT3
Other Name(s): chaperonin containing TCP1 subunit 3 | T-complex protein 1 subunit gamma (isoform a) | OTTHUMP00000231497 | T-complex protein 1, gamma subunit | CCTG | OTTHUMP00000025735 | T-complex protein 1 subunit gamma | TCP-1-gamma | TCP1 (t-complex-1) ring complex, polypeptide 5 | TCPG_HUMAN | CCT-gamma | PIG48 | CCT3 variant 1 | TRIC5 | Chaperonin containing TCP1 subunit 3, transcript variant 1 | hTRiC5 | chaperonin containing TCP1, subunit 3 (gamma) | OTTHUMP00000231494

CCT3: A promising drug target and biomarker for the treatment of neurodegenerative diseases

CCT3 (chaperonin containing TCP1 subunit 3) is a protein that is expressed in various tissues and cells of the human body. It plays a critical role in the structure and function of the endoplasmic reticulum (ER), which is responsible for the delivery and processing of proteins. CCT3 is composed of two subunits, TCP1 and TCP2, and is expressed in high levels in the brain, where it is involved in the formation and maintenance of the ER.

The importance of the ER in the brain is emphasized by the numerous neurodegenerative diseases that affect it, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the accumulation of misfolded proteins, leading to the dysfunction of the ER and the development of neurodegeneration. Therefore, the identification of potential drug targets and biomarkers for these diseases is of great interest.

CCT3 as a drug target

The CCT3 protein has been identified as a potential drug target for the treatment of neurodegenerative diseases due to its involvement in the ER and the formation of misfolded proteins. Several studies have shown that misfolded proteins, such as neurodegenerate protein aggregates, are formed in the ER and are involved in the development of neurodegenerative diseases. Therefore, blocking the activity of CCT3, which is involved in the formation and maintenance of the ER, could be a promising strategy for the treatment of neurodegenerative diseases.

CCT3 as a biomarker

In addition to its potential role as a drug target, CCT3 has also been identified as a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The misfolded proteins that are formed in the ER are not always detectable by standard laboratory techniques, and therefore, the measurement of CCT3 levels in brain tissue could be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

The levels of CCT3 have been shown to be decreased in the brain tissue of individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, CCT3 has been shown to be involved in the formation of neurodegenerate protein aggregates, which are a hallmark of neurodegenerative diseases. Therefore, measuring the levels of CCT3 in brain tissue could be a useful biomarker for the diagnosis and monitoring of neurodegenerative diseases.

Conclusion

In conclusion, CCT3 is a protein that is involved in the formation and maintenance of the endoplasmic reticulum and has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. The inhibition of CCT3 activity could be a promising strategy for the development of new treatments for these conditions. Further research is needed to fully understand the role of CCT3 in the development and progression of neurodegenerative diseases.

Protein Name: Chaperonin Containing TCP1 Subunit 3

Functions: Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of proteins upon ATP hydrolysis (PubMed:25467444). The TRiC complex mediates the folding of WRAP53/TCAB1, thereby regulating telomere maintenance (PubMed:25467444). As part of the TRiC complex may play a role in the assembly of BBSome, a complex involved in ciliogenesis regulating transports vesicles to the cilia (PubMed:20080638). The TRiC complex plays a role in the folding of actin and tubulin (Probable)

The "CCT3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCT3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81